Person:
Schoenfeld, Jonathan

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Schoenfeld

First Name

Jonathan

Name

Schoenfeld, Jonathan
Author's Publications: search.filters.isAuthorOfPublication.063e5d8c-4bc5-4cbc-bd12-e6b2f5685b8f

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Publication
    Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review
    (BioMed Central, 2015) Schoenfeld, Jonathan; Mahadevan, Anand; Floyd, Scott R.; Dyer, Michael A.; Catalano, Paul; Alexander, Brian; McDermott, David F.; Kaplan, Irving D.
    Background: Ipilimumab improves survival in metastatic melanoma patients. This population frequently develops brain metastases, which have been associated with poor survival and are often treated with radiation. Therefore, outcomes following ipilimumab and radiation are of interest, especially given case reports and animal studies suggest combined treatment may generate abscopal responses outside the radiation field. Findings: We reviewed sixteen consecutive melanoma patients who received 1 to 8 courses of radiation, with a sum total of 51, systematically evaluating abscopal responses by following the largest extra-cranial lesion. We also reviewed other series of patients treated with cranial radiation and ipilimumab. Our patients received between 1 and 8 courses of cranial radiation. Four patients received radiation concurrently with ipilimumab. Median survival was 14 months, and 17 months in patients initially treated with SRS. Interestingly, after radiotherapy, there was a 2.8-fold increased likelihood that the rate of extra-cranial index lesion response improved that didn’t reach statistical significance (p = 0.07); this was more pronounced when ipilimumab was administered within three months of radiation (p < 0.01). Conclusion: Our experience and review of recently published series suggest ipilimumab and cranial radiation is well tolerated and can result in prolonged survival. Timing of ipilimumab administration in relation to radiation may impact outcomes. Additionally, our results demonstrate a trend for favorable systemic response following radiotherapy worthy of further evaluation in studies powered to detect potential synergies between radiation and immunotherapy.
  • Thumbnail Image
    Publication
    Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients
    (BioMed Central, 2016) Sridharan, Vishwajith; Margalit, Danielle; Lynch, Stephanie A.; Severgnini, Mariano; Hodi, F. Stephen; Haddad, Robert; Tishler, Roy; Schoenfeld, Jonathan
    Background: Preclinical studies suggest a synergistic effect between radiation, immunotherapy and anti-angiogenic therapy, although the mechanisms are unclear. Angiogenic cytokines are known to affect the immune system, and their levels may be associated with response to immunotherapy. Here, we assess changes in circulating VEGF, as well as angiogenic cytokines angiopoietin-1 and -2 (Ang1, Ang2), and placental growth factor (PLGF) that occur during definitive chemo-radiotherapy in HNSCC patients. Methods: We prospectively collected blood samples from patients receiving definitive radiation with or without chemotherapy. Serum Ang1, Ang2, VEGF, and PLGF were measured via cytokine assays. Results: The majority of patients had advanced stage, node positive HPV-associated oropharyngeal cancer, and received radiation to a median dose of 70 Gy with concurrent cisplatin. Over the course of treatment, serum VEGF and Ang1 levels decreased in 20/24 (84 %, p < 0.0001) and 21/24 (88 %, p < 0.0001) patients, respectively, and Ang2 and PLGF levels increased in 20/24 (83 %, p < 0.0001) patients. Conclusions: We find significant changes in angiogenic cytokines in the majority of HNSCC patients over the course of chemoradiation. Decreases in VEGF caused by radiation may represent one mechanism of potential synergy with immunotherapy. Increases in Ang2 and PLGF are interesting given their link to tumor associated angiogenesis and poor prognosis. Additional studies are needed to explore synergies between anti-angiogenic treatments, immunotherapy, and chemoradiation in HNSCC. Electronic supplementary material The online version of this article (doi:10.1186/s40425-016-0138-9) contains supplementary material, which is available to authorized users.
  • Thumbnail Image
    Publication
    Immunologic profiling of adenoid cystic carcinoma (acc)
    (BioMed Central, 2015) Sridharan, Vishwajith; Liao, Xiaoyun; Chau, Nicole G; Haddad, Robert; El-Naggar, Adel; Freeman, Gordon; Hodi, F Stephen; Rodig, Scott; Dranoff, Glenn; Schoenfeld, Jonathan